Cargando…

Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent

INTRODUCTION: Rheumatoid arthritis (RA) clinical guidelines do not provide strong recommendations for the choice of disease-modifying anti-rheumatic drugs (DMARD) in patients with an inadequate response to methotrexate (MTX), and only limited evidence is available on factors influencing rheumatologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Senbel, Eric, Durand, Frederick, Roux, Baptiste, Badaoui, Fatima-Zohra, Fautrel, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217392/
https://www.ncbi.nlm.nih.gov/pubmed/33939171
http://dx.doi.org/10.1007/s40744-021-00311-1
_version_ 1783710582597222400
author Senbel, Eric
Durand, Frederick
Roux, Baptiste
Badaoui, Fatima-Zohra
Fautrel, Bruno
author_facet Senbel, Eric
Durand, Frederick
Roux, Baptiste
Badaoui, Fatima-Zohra
Fautrel, Bruno
author_sort Senbel, Eric
collection PubMed
description INTRODUCTION: Rheumatoid arthritis (RA) clinical guidelines do not provide strong recommendations for the choice of disease-modifying anti-rheumatic drugs (DMARD) in patients with an inadequate response to methotrexate (MTX), and only limited evidence is available on factors influencing rheumatologist treatment decisions. We aimed to describe therapeutic preferences after the failure of a first-line strategy of MTX in simulated cases of patients with RA. METHODS: Fictional but realistic case-vignettes (n = 64) of patients with RA and an inadequate response to MTX were developed with a combination of RA-poor prognostic factors and comorbidities. Physicians were presented with eight vignettes and chose the most and least appropriate therapeutic option from the following six options randomly proposed 3 by 3: (1) replacing MTX with another csDMARD; (2) combining MTX with one or more csDMARDs; (3) adding a bDMARD of either TNF inhibitors (TNFi), tocilizumab (TCZ), abatacept (ABA), or rituximab (RTZ). A total of 1605 complete case vignettes were produced and randomly assigned to a representative sample of French rheumatologists. For each vignette, whenever a treatment was preferred, one point was incremented for this treatment; if this treatment was the least desired, one point was removed. Preferences were elicited using a normalized best–worst score. RESULTS: Two hundred and four French rheumatologists participated in the study with each vignette being assessed 20–28 times for a completion rate of 94%. TNFi was the first-choice strategy (80% of vignettes), except in cases with a history of infection and pulmonary comorbidity, where ABA was the first preference (85%). TCZ came third in 83% of the cases. Other options were never preferred and repeatedly yielded negative scores. CONCLUSIONS: We observed a conservative trend with TNFi as the main therapeutic choice for patients with RA and inadequate response to MTX. Preference for bDMARD-based strategies increased with the number of RA-poor prognosis factors, whereas an increase in the number of comorbidities resulted in an increased preference for ABA. Understanding clinical decision-making will be particularly important as the therapeutic landscape for RA continues to evolve. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00311-1.
format Online
Article
Text
id pubmed-8217392
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-82173922021-07-01 Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent Senbel, Eric Durand, Frederick Roux, Baptiste Badaoui, Fatima-Zohra Fautrel, Bruno Rheumatol Ther Original Research INTRODUCTION: Rheumatoid arthritis (RA) clinical guidelines do not provide strong recommendations for the choice of disease-modifying anti-rheumatic drugs (DMARD) in patients with an inadequate response to methotrexate (MTX), and only limited evidence is available on factors influencing rheumatologist treatment decisions. We aimed to describe therapeutic preferences after the failure of a first-line strategy of MTX in simulated cases of patients with RA. METHODS: Fictional but realistic case-vignettes (n = 64) of patients with RA and an inadequate response to MTX were developed with a combination of RA-poor prognostic factors and comorbidities. Physicians were presented with eight vignettes and chose the most and least appropriate therapeutic option from the following six options randomly proposed 3 by 3: (1) replacing MTX with another csDMARD; (2) combining MTX with one or more csDMARDs; (3) adding a bDMARD of either TNF inhibitors (TNFi), tocilizumab (TCZ), abatacept (ABA), or rituximab (RTZ). A total of 1605 complete case vignettes were produced and randomly assigned to a representative sample of French rheumatologists. For each vignette, whenever a treatment was preferred, one point was incremented for this treatment; if this treatment was the least desired, one point was removed. Preferences were elicited using a normalized best–worst score. RESULTS: Two hundred and four French rheumatologists participated in the study with each vignette being assessed 20–28 times for a completion rate of 94%. TNFi was the first-choice strategy (80% of vignettes), except in cases with a history of infection and pulmonary comorbidity, where ABA was the first preference (85%). TCZ came third in 83% of the cases. Other options were never preferred and repeatedly yielded negative scores. CONCLUSIONS: We observed a conservative trend with TNFi as the main therapeutic choice for patients with RA and inadequate response to MTX. Preference for bDMARD-based strategies increased with the number of RA-poor prognosis factors, whereas an increase in the number of comorbidities resulted in an increased preference for ABA. Understanding clinical decision-making will be particularly important as the therapeutic landscape for RA continues to evolve. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00311-1. Springer Healthcare 2021-05-03 /pmc/articles/PMC8217392/ /pubmed/33939171 http://dx.doi.org/10.1007/s40744-021-00311-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Senbel, Eric
Durand, Frederick
Roux, Baptiste
Badaoui, Fatima-Zohra
Fautrel, Bruno
Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent
title Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent
title_full Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent
title_fullStr Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent
title_full_unstemmed Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent
title_short Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent
title_sort elicitation of rheumatologist preferences for the treatment of patients with rheumatoid arthritis after the failure of a first conventional synthetic disease-modifying anti-rheumatic agent
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217392/
https://www.ncbi.nlm.nih.gov/pubmed/33939171
http://dx.doi.org/10.1007/s40744-021-00311-1
work_keys_str_mv AT senbeleric elicitationofrheumatologistpreferencesforthetreatmentofpatientswithrheumatoidarthritisafterthefailureofafirstconventionalsyntheticdiseasemodifyingantirheumaticagent
AT durandfrederick elicitationofrheumatologistpreferencesforthetreatmentofpatientswithrheumatoidarthritisafterthefailureofafirstconventionalsyntheticdiseasemodifyingantirheumaticagent
AT rouxbaptiste elicitationofrheumatologistpreferencesforthetreatmentofpatientswithrheumatoidarthritisafterthefailureofafirstconventionalsyntheticdiseasemodifyingantirheumaticagent
AT badaouifatimazohra elicitationofrheumatologistpreferencesforthetreatmentofpatientswithrheumatoidarthritisafterthefailureofafirstconventionalsyntheticdiseasemodifyingantirheumaticagent
AT fautrelbruno elicitationofrheumatologistpreferencesforthetreatmentofpatientswithrheumatoidarthritisafterthefailureofafirstconventionalsyntheticdiseasemodifyingantirheumaticagent